Zeke Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Zeke Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-40,300	Closed	-$2.91M	–	75
2014 Q3	$2.91M	Hold	40,300	–	–	2.64%	8
2014 Q2	$2.51M	Hold	40,300	–	–	2.02%	11
2014 Q1	$2.75M	Hold	40,300	–	–	2.38%	8
2013 Q4	$2.83M	Hold	40,300	–	–	2.6%	10
2013 Q3	$2.91M	Hold	40,300	–	–	2.74%	9
2013 Q2	$2.25M	Buy	+40,300	New	+$2.51M	1.84%	9

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Zeke Capital Advisors's BMRN Position: Q4 2014 in Review

Zeke Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2014, closing a stake of 40,300 shares — an estimated $2.91M sold.

Zeke Capital Advisors first reported a position in BMRN in Q2 2013 and held it in 6 quarters. The position peaked at $2.91M in Q3 2014. 341 funds tracked by Wall St. Rank hold BMRN as of Q4 2014.

Zeke Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Zeke Capital Advisors sold 40,300 BioMarin Pharmaceuticals shares in Q4 2014, an estimated $2.91M.
Zeke Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Zeke Capital Advisors's BioMarin Pharmaceuticals position peaked at $2.91M in Q3 2014.
341 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2014.

Based on Zeke Capital Advisors's 13F filing for Q4 2014, filed 10 Feb 2015.